S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
S&P 500   3,959.13 (+0.64%)
DOW   33,718.76 (+0.36%)
QQQ   284.17 (+1.30%)
AAPL   142.88 (+1.38%)
MSFT   247.75 (+1.38%)
META   115.65 (+1.51%)
GOOGL   94.27 (-0.71%)
AMZN   90.63 (+2.45%)
TSLA   173.94 (-0.06%)
NVDA   171.23 (+6.22%)
NIO   13.41 (+6.60%)
BABA   94.06 (+6.49%)
AMD   70.34 (+0.29%)
T   19.08 (-1.14%)
MU   55.25 (+2.66%)
CGC   3.00 (-7.41%)
F   13.14 (+0.31%)
GE   83.32 (-1.98%)
DIS   92.54 (+0.42%)
AMC   6.12 (+1.16%)
PYPL   74.47 (+0.07%)
PFE   51.56 (+2.63%)
NFLX   309.75 (+0.43%)
NASDAQ:BPTS

Biophytis - BPTS Stock Forecast, Price & News

$0.40
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
▼
$0.43
50-Day Range
$0.35
▼
$0.69
52-Week Range
$0.35
▼
$5.91
Volume
18,554 shs
Average Volume
216,683 shs
Market Capitalization
$8.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Biophytis MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Biophytis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.55) to ($1.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

See Top Rated MarketRank™ Stocks Here
BPTS stock logo

About Biophytis (NASDAQ:BPTS) Stock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Stock News Headlines

December 6, 2022 | americanbankingnews.com
Biophytis S.A. (NASDAQ:BPTS) Short Interest Down 7.7% in November
December 1, 2022 | finance.yahoo.com
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
November 21, 2022 | proactiveinvestors.com
Biophytis sees positive data from PHASE 2-3 COVA CLINICAL STUDY of Sarconeos
November 3, 2022 | finance.yahoo.com
Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study
November 3, 2022 | seekingalpha.com
Biophytis surges 32 % as COVID drug cuts risk of early death in trial
November 3, 2022 | finance.yahoo.com
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
October 31, 2022 | finance.yahoo.com
Biophytis Publishes Its Key Financial Figures As at 30 June 2022, Announces a Restatement of the Financial Statements Published As of December 31st, 2021 and Provides an Update on the Operational Milestones
October 26, 2022 | finance.yahoo.com
Biophytis Announces Receipt of Nasdaq Notice
October 14, 2022 | seekingalpha.com
BPTS Biophytis S.A.
September 15, 2022 | finance.yahoo.com
Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference
September 13, 2022 | finance.yahoo.com
The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd
September 7, 2022 | benzinga.com
Why Coupa Software Is Trading Higher By Over 12%; Here Are 24 Stocks Moving Premarket
September 7, 2022 | seekingalpha.com
Biophytis stock soars 45% as COVID drug cuts risk of death, respiratory failure in trial
August 26, 2022 | wsj.com
Biophytis S.A. ADR
June 30, 2022 | markets.businessinsider.com
Biophytis announces the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for 4 million
June 28, 2022 | apnews.com
Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
June 27, 2022 | finanznachrichten.de
Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD International Congress
June 16, 2022 | apnews.com
Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), a Rare Neuromuscular Disease
June 14, 2022 | seekingalpha.com
BTCM, ANTE and CLNN among mid-day movers
April 8, 2022 | morningstar.com
Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development | Morningstar
April 7, 2022 | seekingalpha.com
Trevi Therapeutics leads healthcare gainers; Aptinyx and Vapotherm among losers
April 7, 2022 | finance.yahoo.com
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
April 7, 2022 | seekingalpha.com
Biophytis details COVID impact on clinical trials for lead asset
April 7, 2022 | markets.businessinsider.com
Biophytis provides updates on Sarconeos (BIO101) clinical development
April 6, 2022 | marketwatch.com
Biophytis ADRs Drop 10% After CFO Evelyne Nguyen Steps Down
See More Headlines
Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

BPTS Company Calendar

Today
12/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPTS
CUSIP
N/A
CIK
1768946
Web
www.biophytis.com
Phone
33-1-44-37-23-00
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.56 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
20,070,000
Free Float
19,325,000
Market Cap
$8.03 million
Optionable
Not Optionable
Beta
0.72

Key Executives

  • Mr. Stanislas Veillet Ph.D. (Age 57)
    Chairman & CEO
    Comp: $474.17k
  • Mr. Philippe J. Rousseau (Age 51)
    Chief Financial Officer
  • Mr. Waly Dioh (Age 53)
    Chief Operating Officer
  • Dr. Pierre J. Dilda (Age 52)
    Chief Scientific Officer
  • Dr. Rene Lafont (Age 76)
    Scientific Advisor & Member of Scientific Advisory Board
  • Mr. Benoit Canolle (Age 44)
    Chief Bus. Officer
  • Mr. Rob van Maanen FFPM (Age 52)
    M.B.A., M.D., Chief Medical Officer
  • Ms. _ Teylan
    Financial Controller

Key Competitors

View All Competitors













BPTS Stock - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings or view top-rated stocks.

How have BPTS shares performed in 2022?

Biophytis' stock was trading at $5.34 at the start of the year. Since then, BPTS shares have decreased by 92.5% and is now trading at $0.40.
View the best growth stocks for 2022 here.

Are investors shorting Biophytis?

Biophytis saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 152,700 shares, a decline of 7.7% from the October 31st total of 165,400 shares. Based on an average trading volume of 198,300 shares, the days-to-cover ratio is currently 0.8 days.
View Biophytis' Short Interest.

When did Biophytis IPO?

(BPTS) raised $20 million in an initial public offering (IPO) on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright acted as the underwriter for the IPO.

What is Biophytis' stock symbol?

Biophytis trades on the NASDAQ under the ticker symbol "BPTS."

How do I buy shares of Biophytis?

Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biophytis' stock price today?

One share of BPTS stock can currently be purchased for approximately $0.40.

How much money does Biophytis make?

Biophytis (NASDAQ:BPTS) has a market capitalization of $8.03 million.

How can I contact Biophytis?

Biophytis' mailing address is SORBONNE UNIVERSITY BC 9 BATIMENT A 4EME ETAGE 4 PLACE JUSSIEU, PARIS I0, 75252. The official website for the company is www.biophytis.com. The company can be reached via phone at 33-1-44-37-23-00.

This page (NASDAQ:BPTS) was last updated on 12/8/2022 by MarketBeat.com Staff